Cantargia AB (“Cantargia”) of Lund, Sweden, and Panorama Research Inc. (“Panorama”), a California based specialist antibody developer, have entered into a collaboration agreement to jointly accelerate Cantargia's second program directed towards autoimmune and inflammatory diseases.
Cantargia’s proprietary antibodies, against the molecular target IL1RAP, will be affinity matured and humanized using Panorama’s proprietary technology. In addition, Panorama will generate cell lines optimized for high level GMP production. Cantargia will be responsible for subsequent down-stream development. Under the terms of the agreement, Panorama will share risk in the project in exchange for a fraction of future incomes from third parties or future sales.
Kristoffer Franzkeit advised Cantargia.
